Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice

Antiviral Research

Volumn 157, Issue , 2018, Pages 18-26

  Hawman, David W ^a   Haddock, Elaine ^a   Meade White, Kimberly ^a   Williamson, Brandi ^a   Hanley, Patrick W ^a   Rosenke, Kyle ^a   Komeno, Takashi ^b   Furuta, Yousuke ^b   Gowen, Brian B ^c   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Research Laboratories   (Japan)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

CCHFV; Crimean Congo hemorrhagic fever virus; Favipiravir; Mouse model; Ribavirin; T 705

Indexed keywords

FAVIPIRAVIR; INTERFERON; RIBAVIRIN; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURVIVOR; TERMINAL DISEASE; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN; ANIMAL; DISEASE MODEL; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; MICE; PYRAZINES; RIBAVIRIN; RNA, VIRAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85049466907     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.06.013     Document Type: Article

References (40)

1. Ascioglu, S., Leblebicioglu, H., Vahaboglu, H., Chan, K.A., Ribavirin for patients with Crimean–Congo haemorrhagic fever: a systematic review and meta-analysis. J. Antimicrob. Chemother. 66 (2011), 1215–1222.
2. Bakir, M., Ugurlu, M., Dokuzoguz, B., Bodur, H., Tasyaran, M.A., Vahaboglu, H., Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J. Med. Microbiol. 54 (2005), 385–389.
3. Baranovich, T., Wong, S.-S., Armstrong, J., Marjuki, H., Webby, R.J., Webster, R.G., Govorkova, E.A., T-705 (favipiravir) induces lethal mutagenesis in influenza a H1N1 viruses in vitro. J. Virol. 87 (2013), 3741–3751.
4. Bente, D.A., Alimonti, J.B., Shieh, W.J., Camus, G., Stroher, U., Zaki, S., Jones, S.M., Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 84 (2010), 11089–11100.
5. Bente, D.A., Forrester, N.L., Watts, D.M., McAuley, A.J., Whitehouse, C.A., Bray, M., Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res. 100 (2013), 159–189.
6. Bereczky, S., Lindegren, G., Karlberg, H., Åkerström, S., Klingström, J., Mirazimi, A., Crimean–Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J. Gen. Virol. 91 (2010), 1473–1477.
7. Çevik, M.A., Erbay, A., Bodur, H., Gülderen, E., Baştuğ A., Kubar, A., Akıncı E., Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int. J. Infect. Dis. 12 (2008), 374–379.
8. Ceylan, B., Calica, A., Ak, O., Akkoyunlu, Y., Turhan, V., Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience. Int. J. Infect. Dis. 17 (2013), e799–801.
9. Dowall, S.D., Carroll, M.W., Hewson, R., Development of vaccines against Crimean-Congo haemorrhagic fever virus. Vaccine 35 (2017), 6015–6023.
10. Duh, D., Nichol, S.T., Khristova, M.L., Saksida, A., Hafner-Bratkovič I., Petrovec, M., Dedushaj, I., Ahmeti, S., Avšič-Županc, T., The complete genome sequence of a Crimean-Congo Hemorrhagic Fever virus isolated from an endemic region in Kosovo. Virol. J., 5, 2008, 7.
11. Elaldi, N., Bodur, H., Ascioglu, S., Celikbas, A., Ozkurt, Z., Vahaboglu, H., Leblebicioglu, H., Yilmaz, N., Engin, A., Sencan, M., Aydin, K., Dokmetas, I., Cevik, M.A., Dokuzoguz, B., Tasyaran, M.A., Ozturk, R., Bakir, M., Uzun, R., Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J. Infect. 58 (2009), 238–244.
12. Erenler, A.K., Kulaksiz, F., Ulger, H., Capraz, M., Tomak, L., Baydin, A., Predictors of Crimean-Congo hemorrhagic fever in the emergency department. Eur. Rev. Med. Pharmacol. Sci. 19 (2015), 3811–3816.
13. Ergonul, O., Crimean-Congo haemorrhagic fever. Lancet Infect. Dis., 6, 2006.
14. Ergonul, O., Tuncbilek, S., Baykam, N., Celikbas, A., Dokuzoguz, B., Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J. Infect. Dis. 193 (2006), 941–944.
15. Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K., In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46 (2002), 977–981.
16. Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., Shiraki, K., Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005), 981–986.
17. Guedj, J., Piorkowski, G., Jacquot, F., Madelain, V., Nguyen, T.H.T., Rodallec, A., Gunther, S., Carbonnelle, C., Mentré F., Raoul, H., de Lamballerie, X., Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med., 15, 2018, e1002535.
18. Haddock, E., Feldmann, F., Hawman, D.W., Zivcec, M., Hanley, P.W., Saturday, G., Scott, D.P., Thomas, T., Korva, M., Avsic-Zupanc, T., Safronetz, D., Feldmann, H., A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. Nat. Microbiol. 3 (2018), 556–562.
19. Koksal, I., Yilmaz, G., Aksoy, F., Aydin, H., Yavuz, I., Iskender, S., Akcay, K., Erensoy, S., Caylan, R., Aydin, K., The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J. Clin. Virol. 47 (2010), 65–68.
20. Leblebicioglu, H., Sunbul, M., Guner, R., Bodur, H., Bulut, C., Duygu, F., Elaldi, N., Cicek Senturk, G., Ozkurt, Z., Yilmaz, G., Fletcher, T.E., Beeching, N.J., Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002-2014: a multicentre retrospective cross-sectional study. Clin. Microbiol. Infect., 22, 2016 387.e1-4.
21. Mardani, M., Jahromi, M.K., Naieni, K.H., Zeinali, M., The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin. Infect. Dis. 36 (2003), 1613–1618.
22. McElroy, A.K., Akondy, R.S., Harmon, J.R., Ellebedy, A.H., Cannon, D., Klena, J.D., Sidney, J., Sette, A., Mehta, A.K., Kraft, C.S., Lyon, M.G., Varkey, J.B., Ribner, B.S., Nichol, S.T., Spiropoulou, C.F., A case of human Lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses. J. Infect. Dis. 215 (2017), 1862–1872.
23. Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., Günther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105 (2014), 17–21.
24. Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Ölschläger, S., Günther, S., Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglected Trop. Dis., 8, 2014, e2804.
25. Ozkurt, Z., Kiki, I., Erol, S., Erdem, F., Yilmaz, N., Parlak, M., Gundogdu, M., Tasyaran, M.A., Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J. Infect. 52 (2006), 207–215.
26. Papa, A., Bino, S., Velo, E., Harxhi, A., Kota, M., Antoniadis, A., Cytokine levels in Crimean-Congo hemorrhagic fever. J. Clin. Virol. 36 (2006), 272–276.
27. Reed, L.J., Muench, H., A simple method of estimating fifty per cent ENDPOINTS12. Am. J. Epidemiol. 27 (1938), 493–497.
28. Safronetz, D., Rosenke, K., Westover, J.B., Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J., Saturday, G., Komeno, T., Geisbert, T.W., Feldmann, H., Gowen, B.B., The broad-spectrum antiviral favipiravir protects Guinea pigs from lethal Lassa virus infection post-disease onset., 5, 2015, 14775.
29. Sissoko, D., Duraffour, S., Kerber, R., Kolie, J.S., Beavogui, A.H., Camara, A.-M., Colin, G., Rieger, T., Oestereich, L., Pályi, B., Wurr, S., Guedj, J., Nguyen, T.H.T., Eggo, R.M., Watson, C.H., Edmunds, W.J., Bore, J.A., Koundouno, F.R., Cabeza-Cabrerizo, M., Carter, L.L., Kafetzopoulou, L.E., Kuisma, E., Michel, J., Patrono, L.V., Rickett, N.Y., Singethan, K., Rudolf, M., Lander, A., Pallasch, E., Bockholt, S., Rodríguez, E., Di Caro, A., Wölfel, R., Gabriel, M., Gurry, C., Formenty, P., Keïta, S., Malvy, D., Carroll, M.W., Anglaret, X., Günther, S., Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. Lancet Glob. Health 5 (2017), e80–e88.
30. Soares-Weiser, K., Thomas, S., Thomson, G., Garner, P., Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect. Dis., 10, 2010, 207.
31. Spengler, J.R., Bente, D.A., Bray, M., Burt, F., Hewson, R., Korukluoglu, G., Mirazimi, A., Weber, F., Papa, A., Second international conference on Crimean-Congo hemorrhagic fever. Antivir. Res. 150 (2018), 137–147.
32. Spengler, J.R., Bergeron, É., Rollin, P.E., Seroepidemiological studies of Crimean-Congo hemorrhagic fever virus in domestic and wild animals. PLoS Neglected Trop. Dis., 10, 2016, e0004210.
33. Stuart, M.C., Kouimtzi, M., Hill, S.R., WHO Model Formulary 2008. 2008, World Health Organization, Geneva.
34. Swanepoel, R., Gill, D.E., Shepherd, A.J., Leman, P.A., Mynhardt, J.H., Harvey, S., The clinical pathology of Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 11:Suppl. 4 (1989), S794–S800.
35. Swanepoel, R., Shepherd, A.J., Leman, P.A., Shepherd, S.P., McGillivray, G.M., Erasmus, M.J., Searle, L.A., Gill, D.E., Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in Southern Africa. Am. J. Trop. Med. Hyg. 36 (1987), 120–132.
36. Tasdelen Fisgin, N., Ergonul, O., Doganci, L., Tulek, N., The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur. J. Clin. Microbiol. Infect. Dis. 28 (2009), 929–933.
37. Tkachenko, E.A., Butenko, A.M., Butenko, S.A., Zaradova, T.I., Chumakov, M.P., Prophylactic characteristics of a protective Crimean hemorrhagic fever vaccine. Crimean Hemorrhagic Fever - Materials of the 3rd Scientific-practical Conference in Rostov-na-donu Region, 1970, 136–138.
38. Vanderlinden, E., Vrancken, B., Van Houdt, J., Rajwanshi, V.K., Gillemot, S., Andrei, G., Lemey, P., Naesens, L., Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob. Agents Chemother. 60 (2016), 6679–6691.
39. Welch, S.R., Scholte, F.E.M., Flint, M., Chatterjee, P., Nichol, S.T., Bergeron, É., Spiropoulou, C.F., Identification of 2′-deoxy-2′-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. Antivir. Res. 147 (2017), 91–99.
40. Zivcec, M., Safronetz, D., Scott, D., Robertson, S., Ebihara, H., Feldmann, H., Lethal Crimean-Congo hemorrhagic fever virus infection in interferon α/β receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J. Infect. Dis. 207 (2013), 1909–1921.